Non-peptide αvβ3 antagonists.: Part 5:: Identification of potent RGD mimetics incorporating 2-aryl β-amino acids as aspartic acid replacements

被引：21

作者：

Brashear, KM ^{[1
]}

Hunt, CA

Kucer, BT

Duggan, ME

Hartman, GD

Rodan, GA

Rodan, SB

Leu, CT

Prueksaritanont, T

Fernandez-Metzler, C

Barrish, A

Homnick, CF

Hutchinson, JH

Coleman, PJ

机构：

[1] Merck Res Labs, Dept Med Chem, W Point, PA 19486 USA

[2] Merck Res Labs, Dept Bone Biol & Osteoporosis Res, W Point, PA 19486 USA

[3] Merck Res Labs, Dept Drug Metab & Pharmacol, W Point, PA 19486 USA

来源：

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | 2002年 / 12卷 / 23期

关键词：

D O I：

10.1016/S0960-894X(02)00743-6

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

A series of novel, highly potent a(y)beta(3) receptor antagonists with favorable pharmacokinetic profiles has been identified. In this series of antagonists, 2-aryl beta-amino acids function as potent aspartic acid replacements. (C) 2002 Published by Elsevier Science Ltd.

引用

页码：3483 / 3486

页数：4

共 22 条

[1] Non-peptide glycoprotein IIb/IIIa inhibitors .17. Design and synthesis of orally active, long-acting non-peptide fibrinogen receptor antagonists [J].

Askew, BC ;

Bednar, RA ;

Bednar, B ;

Claremon, DA ;

Cook, JJ ;

McIntyre, CJ ;

Hunt, CA ;

Gould, RJ ;

Lynch, RJ ;

Lynch, JJ ;

Gaul, SL ;

Stranieri, MT ;

Sitko, GR ;

Holahan, MA ;

Glass, JD ;

Hamill, T ;

Gorham, LM ;

Prueksaritanont, T ;

Baldwin, JJ ;

Hartman, GD .

JOURNAL OF MEDICINAL CHEMISTRY, 1997, 40 (12) :1779-1788

[2]

ASKEW BC, 1996, BIOORG MED CHEM LETT, V6, P339

[3]

COLE DC, 1994, TETRAHEDRON, V50, P9517

[4] Non-peptide αvβ3 antagonists.: Part 4:: Potent and orally bioavailable chain-shortened RGD mimetics [J].

Coleman, PJ ;

Askew, BC ;

Hutchinson, JH ;

Whitman, DB ;

Perkins, JJ ;

Hartman, GD ;

Rodan, GA ;

Leu, CT ;

Prueksaritanont, T ;

Fernandez-Metzler, C ;

Merkle, KM ;

Lynch, R ;

Lynch, JJ ;

Rodan, SB ;

Duggan, ME .

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2002, 12 (17) :2463-2465

[5] Syntheses of 5-and 6-[2,3]-dihydrobenzofuran β-amino acids [J].

Coleman, PJ ;

Hutchinson, JH ;

Hunt, CA ;

Lu, P ;

Delaporte, E ;

Rushmore, T .

TETRAHEDRON LETTERS, 2000, 41 (31) :5803-5806

[6] Prevention and management of osteoporosis - Current trends and future prospects [J].

Compston, JE .

DRUGS, 1997, 53 (05) :727-735

[7] Antibody to beta(3) integrin inhibits osteoclast-mediated bone resorption in the thyroparathyroidectomized rat [J].

Crippes, BA ;

Engleman, VW ;

Settle, SL ;

Delarco, J ;

Ornberg, RL ;

Helfrich, MH ;

Horton, MA ;

Nickols, GA .

ENDOCRINOLOGY, 1996, 137 (03) :918-924

[8] NONPEPTIDE FIBRINOGEN RECEPTOR ANTAGONISTS .7. DESIGN AND SYNTHESIS OF A POTENT, ORALLY-ACTIVE FIBRINOGEN RECEPTOR ANTAGONIST [J].

DUGGAN, ME ;

NAYLOROLSEN, AM ;

PERKINS, JJ ;

ANDERSON, PS ;

CHANG, CTC ;

COOK, JJ ;

GOULD, RJ ;

IHLE, NC ;

HARTMAN, GD ;

LYNCH, JJ ;

LYNCH, RJ ;

MANNO, PD ;

SCHAFFER, LW ;

SMITH, RL .

JOURNAL OF MEDICINAL CHEMISTRY, 1995, 38 (17) :3332-3341

[9] Nonpeptide αvβ3 antagonists.: 1.: Transformation of a potent, integrin-selective αIIbβ3 antagonist into a potent αvβ3 antagonist [J].

Duggan, ME ;

Duong, LT ;

Fisher, JE ;

Hamill, TG ;

Hoffman, WF ;

Huff, JR ;

Ihle, NC ;

Leu, CT ;

Nagy, RM ;

Perkins, JJ ;

Rodan, SB ;

Wesolowski, G ;

Whitman, DB ;

Zartman, AE ;

Rodan, GA ;

Hartman, GD .

JOURNAL OF MEDICINAL CHEMISTRY, 2000, 43 (20) :3736-3745

[10]

Duong L. T., 1998, FRONT BIOSCI, V3, P757

← 1 2 3 →